Atrys Health : Q2 EBITDA in line. FY 2024 guidance reiterated
>Organic sales momentum remains strong, EBITDA accelerates - Q2 2024 group sales were € 57m (+6% y-o-y or +7% excluding -1pp of FX), keeping the solid pace seen in Q1 (+7%), and were broadly in line with our estimate. Precision sales grew by +4% y-o-y to € 32m (vs +10% in Q1 and+13% l-f-l in FY 2023) and were aligned with our numbers., the sequential deterioration is owed to fewer referrals from the Public Health System. Prevention sales posted +8% y-o-y growth to € 2...Atrys Health SA. Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.